Skip to main content
. 2023 Jan 16;76(2):35–40. [Article in Spanish] doi: 10.33588/rn.7602.2022315

Table I.

Demographic and anthropometric characteristics, Epworth sleepiness scale, polysomnography parameters and SXB dose during follow-ups.

Follow-up1 n = 23 Mean (SD) Follow-up2 n = 16 Mean (SD) Follow-up3 n = 10 Mean (SD) p value FU-1 versus FU-2 p value FU-1 versus FU-3
Age (years) 42.2 (13.75) 42.38 (13.95) 44.2 (16.01) NS NS

Sex (m/f) 13/10 8/8 5/5

BMI kg/m2 28.61 (5.19) 27.21 (5.9) 26.4 (6.01) NS NS

SXB dose (g) 4.5 (1.15) 5.25 (1.62) 5.47 (0.86) NS NS

Epworth 17.67 (7.5) 18 (7) 20.5 (4.9) NS NS

Sleep efficiency (%) 78.57 (13.17) 78.99 (8.64) 78.92 (8.68) NS NS

Sleep latency (min) 8.02 (5.68) 8.65 (7.95) 6.5 (3.35) NS NS

REM sleep latency (min) 33.17 (48.01) 33.31 (48.01) 35.06 (50.34) NS NS

TST (min) 382.63 (55.16) 377.96 (52.25) 384.9 (46.52) NS NS

WASO (min) 90.75 (59.81) 95.37 (41.52) 102.25 (40.4) NS NS

Awakenings/hour (n.º/h) 17.68 (12.11) 15.93 (10.74) 12.3 (4.39) NS NS

Stage N1 (minutos) 68.26 (28.39) 78.12 (54.97) 104.5 (80.49) NS 0.03a

Stage N1 (%) 17.61 (7.09) 17.39 (10.24) 21.37 (16.48)

Stage N2 (minutos) 136.674 (52.01) 150.37 (48.41) 148.45 (52.72) 0.03a NS

Stage N2 (%) 33.84 (9.5) 35.01 (10.89) 30.32 (10.5)

Stage N3 (minutos) 102.02 (54.64) 87.78 (48.1) 89.65 (55.59) NS NS

Stage N3 (%) 26.39 (13.74) 21.11 (12.61) 18.48 (11.7)

Stage REM (minutos) 50.95 (16.65) 50.87 (20.04) 42.35 (19.77) NS NS

Stage REM (%) 13.09 (4.58) 11.68 (4.09) 8.66 (3.93)

AHI (Median, IQR) 2.65 (0-9.6) 2.8 (0-6.6) 4.05 (3.1-19) NS 0a

PLMI (Median, IQR) 0 (0-7.3) 17.65 (3.6-27.22) 19.35 (15.2-31.4) 0.01a 0.04a

AHI: apnea-hypopnea index; BMI: body mass index; IQR: interquartile range; NS: not significant; PLMI: periodic leg movement index; PSG: polysomnography; REM: rapid eye movements; SXB: sodium oxybate; TST: total sleep time; WASO: wake after sleep onset.

a

Significant differences at p < 0.05.